Research article
Active immunization to tumor necrosis factor-α is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis
-
* Corresponding author: Marie-Christophe Boissier boissier@univ-paris13.fr
1 EA4222, Li2P, University of Paris 13, 74 rue Marcel Cachin, 93000, Bobigny, France
2 Rheumatology Department, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), 125 rue de Stalingrad, 93000, Bobigny, France
3 Neovacs SA, 3-4 impasse Reille, 75014, Paris, France
4 Debiopharm SA, Chemin Messidor 5-7, Case Postale 5911, CH-1002, Lausanne, Switzerland
Arthritis Research & Therapy 2009, 11:R195 doi:10.1186/ar2897
Published: 23 December 2009Abstract
Introduction
Passive blockade of tumor necrosis factor-alpha (TNF-α) has demonstrated high therapeutic efficiency in chronic inflammatory diseases, such as rheumatoid arthritis, although some concerns remain such as occurrence of resistance and high cost. These limitations prompted investigations of an alternative strategy to target TNF-α. This study sought to demonstrate a long-lasting therapeutic effect on established arthritis of an active immunotherapy to human (h) TNF-α and to evaluate the long-term consequences of an endogenous anti-TNF-α response.
Methods
hTNF-α transgenic mice, which spontaneously develop arthritides from 8 weeks of age, were immunized with a heterocomplex (TNF kinoid, or TNF-K) composed of hTNF-α and keyhole limpet hemocyanin after disease onset. We evaluated arthritides by clinical and histological assessment, and titers of neutralizing anti-hTNF-α antibody by enzyme-linked immunosorbent assay and L929 assay.
Results
Arthritides were dramatically improved compared to control mice at week 27. TNF-K-treated mice exhibited high levels of neutralizing anti-hTNF-α antibodies. Between weeks 27 and 45, all immunized mice exhibited symptoms of clinical deterioration and a parallel decrease in anti-hTNF-α neutralizing antibodies. A maintenance dose of TNF-K reversed the clinical deterioration and increased the anti-hTNF-α antibody titer. At 45 weeks, TNF-K long-term efficacy was confirmed by low clinical and mild histological scores for the TNF-K-treated mice. Injections of unmodified hTNF-α did not induce a recall response to hTNF-α in TNF-K immunized mice.
Conclusions
Anti-TNF-α immunotherapy with TNF-K has a sustained but reversible therapeutic efficacy in an established disease model, supporting the potential suitability of this approach in treating human disease.